UPDATEOn October 3, the Biden-Harris Administration announced that manufacturers of all 10 drugs selected for negotiation signed agreements to participate in the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

UPDATE

On October 3, the Biden-Harris Administration announced that manufacturers of all 10 drugs selected for negotiation signed agreements to participate in the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

Key TakeawaysFor the first time, the federal government will negotiate with drug makers in order to reduce the cost of certain prescription drugs.The first 10 drugs selected lack suitable generic alternatives.These discounts only apply to people on Medicare.

Key Takeaways

For the first time, the federal government will negotiate with drug makers in order to reduce the cost of certain prescription drugs.The first 10 drugs selected lack suitable generic alternatives.These discounts only apply to people on Medicare.

When older adults are facing serious health issues such as heart disease, diabetes, or cancer, their diagnosis may be the least of their worries. Even afterMedicare Part Dbenefits, some lifesaving drugs cost patients thousands out of pocket every year. Annual price increases make it an uphill battle—until now.

As part of the Inflation Reduction Act (IRA) of 2022, 10 drugs were chosen for negotiation this year, with more to come in subsequent years. For millions of Americans who rely on these drugs, lowering drug prices may significantly impact their health and standard of living.

How the Inflation Reduction Act Will Reduce Health Care Costs for Seniors

Drugs Chosen Impact Millions of Medicare Recipients

This is the first year that negotiation has been allowed for drug prices, and the lowered prices will only affect prescriptions purchased within the Medicare system. Many of the drugs treat the same things: diabetes, heart disease, arthritis, and cancer. Not only do these drugs treat very common ailments, but they all do so in a way that lacks a suitable generic alternative.

TheWhite House saysthat older adults paid $3.4 billion in out-of-pocket costs on these 10 drugs alone in 2022.

How Long Until the New Prices Take Effect?

The initial 10 drugs were chosen from a list of 50 of the most prescribed drugs in the Medicare Part D system. And while the news of negotiations is promising, this is just a first step towards lowering drug prices, according toLeigh Purvis, MPA, Prescription Drug Policy Principal for the AARP Public Policy Institute. In a recent webinar, she outlined the process.

Now that the drugs have been chosen, each drug maker will have until October 2, 2023, to sign agreements to participate in the program and submit data about their products and pricing. Patients will also have the opportunity to submit data about alternatives to these drugs, how the chosen drugs have impacted specific populations, and testify to unmet needs. After this, CMS will hold open listening sessions with patients to define their needs and concerns.

“In terms of developing that initial offer, CMS has been very clear,” Purvis says. “It’s going to start with evidence related to therapeutic alternatives and then consider other factors like cost of research and development and production and distribution of that selected drug.”

Impact for Patients

“It’s widely understood that when people adhere to their drugs and use their drugs, they are healthier,” Mitchell told Verywell. “It actually saves our health care system money because they are being kept healthy.”

Although only 10 drugs are up for negotiations, Purvis said that savings will be felt across the Medicare population. With lowered prices for these drugs, CMS will be able to redistribute funds to offset other costs, lowering the financial impact across the board.

“When you are paying for high prescription drug prices, you’re either paying for them as a patient or paying through your premiums, or through your cost-sharing,” Purvis said. “They will see savings as a result of the negotiation, regardless of if they are taking the drug themselves.”

What This Means For YouPrescription drug price negotiations are just one portion of the IRA aimed at making care more affordable to older adults. Although broadly supported on both sides of the aisle, the moves aren’t without controversy. Several pharmaceutical companies have filed suits to stop the action, so there may be blockages along the way.If the negotiations go smoothly, Medicare recipients should begin seeing more affordable drugs as soon as 2026. Even if you aren’t prescribed one of the affected drugs, the overall cost burden of specialty drugs should be alleviated, creating more opportunities to lower premiums.

What This Means For You

Prescription drug price negotiations are just one portion of the IRA aimed at making care more affordable to older adults. Although broadly supported on both sides of the aisle, the moves aren’t without controversy. Several pharmaceutical companies have filed suits to stop the action, so there may be blockages along the way.If the negotiations go smoothly, Medicare recipients should begin seeing more affordable drugs as soon as 2026. Even if you aren’t prescribed one of the affected drugs, the overall cost burden of specialty drugs should be alleviated, creating more opportunities to lower premiums.

Prescription drug price negotiations are just one portion of the IRA aimed at making care more affordable to older adults. Although broadly supported on both sides of the aisle, the moves aren’t without controversy. Several pharmaceutical companies have filed suits to stop the action, so there may be blockages along the way.

If the negotiations go smoothly, Medicare recipients should begin seeing more affordable drugs as soon as 2026. Even if you aren’t prescribed one of the affected drugs, the overall cost burden of specialty drugs should be alleviated, creating more opportunities to lower premiums.

1 SourceVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.KFF.FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

1 Source

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.KFF.FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

KFF.FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

Meet Our Medical Expert Board

Share Feedback

Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit

Was this page helpful?

Thanks for your feedback!

What is your feedback?OtherHelpfulReport an ErrorSubmit

What is your feedback?

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.Cookies SettingsAccept All Cookies

By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

Cookies SettingsAccept All Cookies